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Albumin administration prevents 
neurological damage and death in 
a mouse model of severe neonatal 
hyperbilirubinemia
Simone Vodret1, Giulia Bortolussi1, Andrea B. Schreuder2, Jana Jašprová3, Libor Vitek3, 
Henkjan J. Verkade2 & Andrés F. Muro1
Therapies to prevent severe neonatal unconjugated hyperbilirubinemia and kernicterus are 
phototherapy and, in unresponsive cases, exchange transfusion, which has significant morbidity 
and mortality risks. Neurotoxicity is caused by the fraction of unconjugated bilirubin not bound to 
albumin (free bilirubin, Bf). Human serum albumin (HSA) administration was suggested to increase 
plasma bilirubin-binding capacity. However, its clinical use is infrequent due to difficulties to address 
its potential preventive and curative benefits, and to the absence of reliable markers to monitor 
bilirubin neurotoxicity risk. We used a genetic mouse model of unconjugated hyperbilirubinemia 
showing severe neurological impairment and neonatal lethality. We treated mutant pups with 
repeated HSA administration since birth, without phototherapy application. Daily intraperitoneal 
HSA administration completely rescued neurological damage and lethality, depending on dosage 
and administration frequency. Albumin infusion increased plasma bilirubin-binding capacity, 
mobilizing bilirubin from tissues to plasma. This resulted in reduced plasma Bf, forebrain and 
cerebellum bilirubin levels. We showed that, in our experimental model, Bf is the best marker to 
determine the risk of developing neurological damage. These results support the potential use of 
albumin administration in severe acute hyperbilirubinemia conditions to prevent or treat bilirubin 
neurotoxicity in situations in which exchange transfusion may be required.
About 60% of healthy, term neonates, and almost all pre-term babies, will develop physiological neonatal 
jaundice [elevated unconjugated bilirubin (UCB) plasma levels] in the first week of life1,2, caused in most 
cases by a temporary delay in the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene acti-
vation. This condition is usually considered benign3. However, in some babies uncontrolled unconjugated 
hyperbilirubinemia may develop due to other concurrent causes, such as pre-term birth, mutations in 
the UGT1A1 gene (Crigler-Najjar syndrome), hemolytic conditions (such as glucose-6-phoshate dehy-
drogenase deficiency, other genetic disorders affecting hemoglobin or the erythrocyte membrane, or 
immune mediated hemolysis), sepsis, or other unknown stressors, resulting in acute bilirubin enceph-
alopathy (kernicterus) and, eventually, death2–4. The incidence of kernicterus is about 0.4 to 2.7 per 
100,000 live births4,5, raising to about 1.8 per 1000 live births considering preterm infants born with less 
than 30 weeks of gestational age6. Yet, it is significantly more frequent in underdeveloped and developing 
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countries5,7–10, being a “silent” cause of significant neonatal morbidity and mortality. In fact, it is ranked 
as one of the three top causes of death among African newborns9,11–13.
Jaundice is normally treated with phototherapy (PT), which for most patients has sufficient efficacy 
and convenience, with high safety and low costs. However, jaundiced infants who fail to respond to 
PT, or are severely hyperbilirubinemic upon first presentation, are treated with a more invasive and 
inherently more dangerous alternative, such as exchange transfusion (ET). ET is implemented only in 
specialized centers and carries a significant risk of morbidity and mortality from vascular accidents, 
cardiac complications, biochemical and haematological disturbances2,14. The overall mortality rate from 
the procedure, having high variability among the different centers, is normally quoted as being 0.3–0.7%, 
although it may reach up to 17% in developing countries15. Adverse events may amount up to 36%, 
including catheter-related complications, sepsis, thrombocytopenia, and hypocalcemia9,16–20. Therefore, 
the development of alternative strategies to reduce the risk of bilirubin encephalopathy in a rapid and 
efficacious manner is a clinical need.
At a physiological pH bilirubin is poorly water-soluble and therefore needs to be metabolized in 
the liver to allow its disposal. Due to the high affinity of albumin for unconjugated bilirubin21, UCB is 
transported via the circulation to the liver bound to albumin22. Neurological damage is produced by the 
small fraction of UCB not bound to albumin (free bilirubin, Bf). Bf, normally present at levels lower 
than 0.1% of total bilirubin in plasma23, is capable of crossing the blood-brain-barrier and disrupting 
several essential cellular functions, resulting in neuronal cell death24,25. Therefore, a possible strategy to 
avoid bilirubin accumulation in the brain could be to increase the bilirubin-binding capacity within the 
intravascular compartment by albumin supplementation. Administration of albumin, prior to ET, has 
been performed in the pediatric clinic to increase the efficacy of this procedure26–32. Nonetheless, the 
therapeutic use of albumin is not routinely used to treat severe neonatal jaundice due to the absence of 
strong experimental support14.
Pre-clinical studies performed by our group in the Gunn rat model of hyperbilirubinemia demon-
strated the short term efficacy of a single albumin infusion in lowering plasma Bf, brain bilirubin levels 
and preventing brainstem evoked potential alterations33,34. However, the mild phenotype of the Gunn 
rats did not allow the study of the long-term effect or the therapeutic efficacy of the treatment to save 
lives was determined. Hyperbilirubinemia in Gunn rats is normally not associated with kernicterus, and 
they develop acute central nervous system dysfunction, and eventually irreversible brain damage, only 
when further challenged by administration of bilirubin-albumin displacers (e.g. sulphonamides) or of 
erythrocyte-lysing agents such as phenylhydrazine35.
In the present work, we performed one crucial step forward: we tested the long-term benefits of 
albumin administration in a more severe and clinically relevant lethal mouse model of neonatal hyper-
bilirubinemia36,37, without the application of the standard phototherapy treatment. These mice lack 
bilirubin-conjugation activity and develop severe hyperbilirubinemia soon after birth36,37, closely mim-
icking the human pathology. Mutant mice show important cerebellar defects, neuronal cell death and die 
shortly after birth due to bilirubin neurotoxicity36.
We show here that repeated albumin administration, without PT application, prevents bilirubin-induced 
neurological damage and lethality. We demonstrate that the albumin dosage and administration fre-
quency are determinants for preventing bilirubin neurotoxicity. The present work also provides evidence 
that in our experimental model Bf is the best predictor of neurological damage induced by bilirubin, 
among the most commonly used clinical markers.
Results
Daily human serum albumin (HSA) administration increases survival of the mutant mice. 
Figure  1 shows the effects of intraperitoneal (i.p.) administration of human serum albumin (HSA) on 
the survival of mice, at different time intervals and dosages. Administration of either 2.5 g/kg or 5.0 g/
kg HSA doses every 48 h (HSA 2.5 g/kg/48 h and HSA 5.0 g/kg/48 h, respectively) effectively delayed 
mortality of mutant mice (50% survival at post-natal day 17 and 18, P17 and P18, respectively, Fig. 1), 
but all mutant mice died before day 27 after birth. HSA administration of 2.5 g/kg every 24 h (HSA 
2.5 g/kg/24 h) resulted in higher survival of mice (50% mortality at P22), with one out of 11 treated 
mice surviving beyond 30 days. Finally, daily treatment with HSA 5.0 g/kg (HSA 5.0 g/kg/24 h) or 7.5 g/
kg (HSA 7.5 g/kg/24 h) resulted in about 95% survival of mice beyond 30 days (Fig.  1). These results 
strongly underscored that HSA administration reduces mortality in this mouse model in a dose and 
time-dependent manner.
To determine potential side effects of albumin treatment, we analyzed several parameters. We moni-
tored HSA-treated animals by weighing them daily since birth, and we did not observe any evident alter-
ation in their weight curve, routine behavior and general aspect, indicating that mice tolerated well the 
treatment, even at the highest dosages (Supplementary Fig. 1A). Moreover, we determined ALT and AST 
at P15 in animals receiving daily HSA administration to evaluate possible liver damage (Supplementary 
Fig. 1B–C). We observed that plasma alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) activities were not significantly different from wild type (WT) and mutant (MUT) uninjected 
controls, indicating the absence of liver damage by HSA daily treatment.
Then, we determined plasma albumin and total bilirubin concentration in treated mice at P15, 24 h 
after the P14 HSA injection in all treated groups (Fig. 2). Since untreated mutant mice did not survive 
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longer than P15 [36 and Fig. 1, red line], we therefore selected as control group an experimental condition 
that allows the animals to survive longer, by temporarily treating them with PT [12 h/day since birth up 
to P10 (P0-P10 PT), and then transferring the mice to normal light conditions). Bilirubin rapidly raises 
after discontinuation of the PT treatment, being at P15 not any longer affected by the PT treatment36. 
Under these experimental conditions, only about ~5% of P0-P10 PT – treated mutant mice survived after 
P30 (Fig. 1, orange line). Albumin treatment, as expected, increased plasma albumin concentrations in a 
dose-dependent manner, up to a maximum increase of about two-fold (Fig. 2A). No differences in basal 
albumin concentration between P0-P10 PT mutant and WT mice were observed, or between WT- and 
HSA-treated mutant mice, within each treatment (Fig. 2A and Table 1).
Albumin treatment increased plasma bilirubin concentration in HSA-treated mutant mice, up 
to two-fold higher than in controls (HSA 7.5 g/kg/24 h vs. P0-P10 PT; 29.4 mg/dL and 14.95 mg/dL, 
respectively, t-test, p < 0.001, Fig. 2B). Plasma bilirubin levels of HSA-treated WT mice were similar to 
untreated WT mice, in the range of 0.5 mg/dL (Table 1).
Daily administration of 5.0 g/kg albumin was the minimal dosage resulting in virtually complete sur-
vival of mutant mice, while the 5.0 g/kg dose administered every 48 h resulted in death of all animals. 
This apparent critical dosage scheme led us to compare the relevant parameters at P15.
Figure 2C shows the strong correlation between plasma albumin and plasma total bilirubin (TB) con-
centration values in the HSA 5.0 g/kg/24 h, HSA 5.0 g/kg/48 h and P0-P10 PT groups (Fig. 2C; r2 = 0.84, 
p < 0.0001, Correlation test, Pearson coefficient). Since the cause of neurotoxicity is the bilirubin accu-
mulated in the tissue, we then determined the levels of tissue bilirubin in forebrain and cerebellum, 
which were 30–40% lower in both HSA 5.0 g/kg/24 h and HSA 5.0 g/kg/48 h groups, compared with 
control mutant mice (P0-P10 PT group) (Fig. 3A). Interestingly, there was no difference between the 24 h 
and the 48 h-treated groups. Indeed, determination of plasma Bf at P15 showed that albumin supplemen-
tation significantly reduced the free fraction of bilirubin capable of causing damage (Fig. 3B, p < 0.001, 
ANOVA). In fact, Bf in HSA-treated animals was about 33% of the P0-P10 PT control group, but there 
was no difference between the two HSA-treated groups, which received different frequencies of injection.
Next, we performed histological analysis of the cerebellum, the most affected brain region36,37, at P15. 
Mutant mice treated with HSA 5.0  g/kg/24  h showed cerebellar layers similar to WT, while we observed 
an important reduction of the layers’ depth in the HSA 5.0  g/kg/48 h group (50% reduction in the inter-
nal granular layer and molecular layer, Fig. 4A). As previously observed, the P0-P10 PT treatment was 
sufficient to prevent major abnormalities in cerebellar development (Fig.  4A,B)36. Calbindin-specific 
staining of Purkinje cells (PCs) showed normal PCs density and dendritic arborization in both P0-P10 
PT and HSA 5.0 g/kg/24 h animals, but a 40–50% reduction in the number of PC and their dendritic 
arborization in the HSA 5.0 g/kg/48 h group (Fig. 4B). Importantly, HSA-rescued animals did not show 
any obvious motor-coordination impairment compared to WT littermates, as assessed by the accelerating 
rotarod test at 1 month of age (Fig. 4C). These results were in line with the histological analysis, confirm-
ing that repeated HSA administration prevents bilirubin-induced neurological damage.
Figure 1. Administration of HSA increase survival of mutant mice. Kaplan-Meier survival curve of 
FVB/NJ Ugt1 mutant mice. Mutant mice were treated with IP injections of albumin (2.5, 5.0 and 7.5 g/kg) 
from P2 to P20 every 24 h or 48 h, as indicated. The line color/type indicates the different treatments (red 
line, untreated mutant mice; orange line, mutant mice treated with phototherapy from P0 to P10; other 
lines, HSA treatments). p < 0.0001, Log-rank (Mantel-Cox) test. The number of animals per treatment is as 
follows: UNTR (n = 21), P0-P10 PT (n = 24), HSA 2.5 g/kg/48 h (n = 15), HSA 2.5 g/kg/24 h (n = 11), HSA 
5.0 g/kg/48 h (n = 15), HSA 5.0 g/kg/24 h (n = 15), HSA 7.5 g/kg/24 h (n = 12) UNTR, untreated mice; HSA, 
human serum albumin; PT, phototherapy; P, post-natal day.
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Frequency of HSA administration is crucial to prevent bilirubin accumulation in brain and 
bilirubin-induced neurological damage. Since the differences in histology and survival between 
the 5.0 g/kg/24 h and 5.0 g/kg/48 h-treated mutant mice were not supported by any difference in the 
parameters determined at P15 (TB, Bf and tissue bilirubin), we reasoned that this could be related to 
the timing of albumin administration (both groups had received the last HSA dose 24 h before, at P14).
Therefore, we investigated the second 24 h of the HSA administration in the 5.0 g/kg/48 h group. At 
this time point (P16), the HSA 5.0 g/kg/48 h group received the last HSA injection 48 h before the anal-
ysis (at P14). Conversely, only 24 h passed for the HSA 5.0 g/kg/24 h-treated animals that received the 
last injection at P15 (Fig. 5).
Figure 2. Dose-dependent effect of albumin administration on plasma values. (A) Plasma albumin levels 
in untreated and HSA injected mutant and WT mice at P15. Values represent mean ± SD (g/L). t-test, not 
significant. P0-P10 PT (WT = 20, MUT = 20), HSA 2.5 g/kg/24 h (WT = 5, MUT = 7), HSA 5.0 g/kg/48 h 
(WT = 4, MUT = 15), HSA 5.0 g/kg/24 h (WT = 5, MUT = 15), HSA 7.5 g/kg/24 h (WT = 1, MUT = 3); (B) 
Total plasma bilirubin levels in mutant mice at P15. Values represent mean ± SD (mg/dL). One-way ANOVA 
test, ***p < 0.001. P0-P10 PT (n = 20), HSA 2.5 g/kg/24 h (n = 7), HSA 5.0 g/kg/48 h (n = 15), HSA 5.0 g/
kg/24 h (n = 15), HSA 7.5 g/kg/24 h (n = 3); (C) Correlation test between plasma albumin and total bilirubin 
(TB) in P0-P10 PT, HSA 5.0 g/kg/48 h and HSA 5.0 g/kg/24 h-treated mutant mice. Each dot corresponds 
to a single animal. Correlation test, Pearson coefficient WT, wild-type; MUT, mutant; HSA, human serum 
albumin; PT, phototherapy; P, post-natal day; TB, total bilirubin; ns, not significative.
www.nature.com/scientificreports/
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Plasma albumin determination showed a significant reduction of about 25% between P15 and P16 in 
the HSA 5.0 g/kg/48 h group (Fig. 5A, p < 0.001, t-test). On the contrary, no differences were observed 
for the 5.0 g/kg/24 h and P0-P10 PT groups at those time points.
Plasma Bf values 48 h after the last injection triplicated (from P15 to P16) in the HSA 5.0 g/kg/48 h 
group (Fig.  5B), reaching values of the untreated control group. In contrast, Bf levels remained steady 
and low in the HSA 5.0 g/kg/24 h group.
Determination of tissue bilirubin showed a significant increase in the P0-P10 PT control group, both 
in the forebrain and in cerebellum, associated with the physiological raise in TB plasma levels between 
P15 and P16 (Supplementary Fig. 2; Fig. 5C). In addition, in the 5.0 g/kg/48 h-treated group tissue bil-
irubin rose significantly as a consequence of the concomitant increase of Bf in plasma (Fig.  5B). In 
contrast, there was no variation in tissue UCB in the HSA 5.0 g/kg/24 h group, strongly indicating that 
daily HSA infusions can keep under safe therapeutic levels tissue UCB, avoiding bilirubin toxicity and 
neurological damage.
Predictive markers of bilirubin-induced neurological damage. Since cerebellum is the most 
affected brain region, we selected cerebellar bilirubin content as an estimator of neurological damage. 
Treatment Age
TB (mg/dL) Plasma albumin (g/L)
WT MUT WT MUT
P0-P10 PT P15 0.2 ± 0.1 (20) 14.9 ± 1.6 (21)*** 16.2 ± 1.8 (20) 15.7 ± 2.1 (21) ns
HSA 2.5 g/kg/24h P15 0.6 ± 0.1 (5) 28.8 ± 2.6 (7)*** 22.9 ± 0.5 (5) 24.1 ± 1.4 (7) ns
HSA 5.0 g/kg/48h P15 0.5 ± 0.1 (4) 24.3 ± 2.6 (15)*** 26.1 ± 1.4 (4) 26.4 ± 2.6 (15) ns
HSA 5.0 g/kg/24h P15 0.7 ± 0.1 (5) 25.1 ± 2.8 (15)*** 27.4 ± 2.9 (5) 28.9 ± 2.2 (15) ns
HSA 7.5 g/kg/24h P15 1.7 (1) 29.4 ± 1.6 (3) 35.9 ± 0 (1) 35.3 ± 1.1 (3)
P0-P10 PT P16 0.2 ± 0.1 (7) 19.3 ± 3.5 (6)*** 16.2 ± 1.1 (7) 15.8 ± 2.8 (6) ns
HSA 5.0 g/kg/48h P16 0.3 ± 0.2 (7) 27.7 ± 2.8 (14)*** 24.2 ± 4.2 (7) 21.7 ± 4.1 (14) ns
HSA 5.0 g/kg/24h P16 0.8 ± 0.2 (6) 31.2 ± 4.2 (7)*** 29.1 ± 4.4 (6) 29.5 ± 4.6 (7) ns
Untreated P30 0.1 ± 0.1 (4) ND 18.3 ± 1.8 (4) ND
HSA 5.0 g/kg/24h P30 0.1 ± 0.1 (5) 8.2 ± 1.2 (7)*** 19.2 ± 1.5 (7) 16.7 ± 2.0 (7) ns
HSA 7.5 g/kg/24h P30 0.1 ± 0.1 (5) 7.4 ± 1.05 (6)*** 18.7 ± 2.3 (6) 17.9 ± 1.7 (6) ns
Table 1. Plasma total bilirubin and albumin levels. ND, not determined as untreated mutant mice do 
not survive up to P30. The number of animals is indicated between parenthesis. *** indicates a p < 0.001  
(t-test between WT and treated mutant mice, within each treatment).
Figure 3. Effect of albumin supplementation on tissue bilirubin-binding and Bf. (A) Brain UCB 
levels (forebrain and cerebellum) in P0-P10 PT (n = 8), HSA 5.0 g/kg/48 h (n = 6) and HSA 5.0 g/kg/24 h 
(n = 7)-treated mutant mice at P15. Values represent mean ± SD (nmol/mg). One-way ANOVA test, 
**p < 0.01, ***p < 0.001. (B) Free bilirubin (Bf) analysis in plasma in P0-P10 PT (n = 19), HSA 5.0 g/
kg/48 h (n = 9) and HSA 5.0 g/kg/24 h (n = 8) mutant mice at P15. Values represent mean ± SD (μ g/dL). 
One-way ANOVA test, ***p < 0.001 HSA, human serum albumin; PT, phototherapy; P, post-natal day; UCB, 
unconjugated bilirubin; ns, not significative.
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We evaluated which parameter better predicted neurological damage and survival by plotting individual 
data of plasma TB concentration, B/A ratio and Bf as a function of tissue bilirubin levels at P16 (Fig. 6).
We observed that neither plasma TB nor bilirubin/albumin B/A ratio correlated with cerebellar 
bilirubin content, being the distribution of both populations overlapping with that of the HSA 5.0 g/
kg/24 h group (Fig.  6A, B; r2 = 0.08 and 0.35, respectively; p = 0.2, p < 0.01, respectively, Correlation 
test, Pearson coefficient). In contrast, plasma Bf values showed a more clear separation between both 
treatments. The Bf of all HSA 5.0 g/kg/24 h animals were clearly distinct from the Bf values of the 
two other groups (HSA 5.0 g/kg/48 h and P0-P10 PT) (Fig. 6C, r2 = 0.62, p < 0.0001, Correlation test, 
Pearson coefficient), indicating that Bf better predicts bilirubin neurotoxicity in our experimental 
model, as determined at P16.
Figure 4. Neurological assessment of albumin treatment. WT, P0-P10 PT, HSA 5.0/48h and HSA 
5.0/24h-treated mutant mice cerebellar analysis at P15. (A) Left panel, Nissl staining of cerebellar internal 
granular layer and molecular layer. Right panel, layer depth quantification. Scale bar 100  μ m. Values 
represent mean ± SD (μ m). One-way ANOVA test, *p < 0.05, **p < 0.01, ***p < 0.001. WT(n = 7), P0-P10 
PT (n = 4), HSA 5.0 g/kg/48 h (n = 3), HSA 5.0 g/kg/24 h (n = 3); (B) Left panel, representative fluorescent 
immunohistochemistry. PCs were stained with anti-calbindin1 antibody (green) and nuclei with Hoecsht 
stain (blue). Right panel, quantification of PCs is represented in the bar. Scale bar 50 μ m. Values represent 
mean ± SD (cell/mm). One-way ANOVA test, ***P < 0.001. WT (n = 9), P0-P10 PT (n = 4), HSA 5.0 g/
kg/48 h (n = 5), HSA 5.0 g/kg/24 h (n = 5); (C) Motor coordination of WT (n = 24) and rescued treated 
mutant mice (20) on rotarod at 1 month of age. Values represent mean ± SD (s). t-test, not significant. ML, 
molecular layer, IGL, internal granular layer, PC, Purkinje cell HSA, human serum albumin; WT, wild-type; 
MUT, mutant; PT, phototherapy; P, post-natal day; UCB, unconjugated bilirubin; ns, not significative.
www.nature.com/scientificreports/
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Discussion
Aiming to decrease bilirubin toxicity in the brain, our group recently demonstrated that the combination 
of a single HSA infusion with PT was very effective in lowering plasma free unconjugated bilirubin, 
brain bilirubin levels and preventing brainstem evoked potential alterations, using the Gunn rat33,34, 
a non-lethal model of hyperbilirubinemia. In the present work, we made one crucial step forward by 
using a mouse model for hyperbilirubinemia showing early neonatal lethality36,37 and treating mutant 
pups with repeated HSA infusions since birth, without the application of PT. In this way, we evaluated 
the effectiveness of the long-term sustained increase in bilirubin-binding capacity in plasma to prevent 
neonatal neurological damage and death.
We demonstrated that daily HSA administration during postnatal development was necessary and 
sufficient to rescue neurological damage and lethality. Rescued mutant mice showed normal motor coor-
dination abilities, no histological abnormalities in the cerebellum and normal albumin levels at follow 
up (at postnatal day 30).
Moreover, HSA administration clearly increased bilirubin-binding capacity in plasma, evident by the 
drop in Bf levels and by the impressive increase in plasma TB in treated animals, indicating that that 
the therapeutic efficacy of albumin was thus not mediated by a total bilirubin lowering effect, but by the 
reduction of Bf concentration.
Our data strengthen the concept that TB increase in plasma results from the mobilization of bilirubin 
from tissues. Most importantly, despite the extreme hyperbilirubinemia in the plasma compartment, 
HSA-treated animals survived without any adverse effect, as a consequence of having much lower tissue 
UCB levels.
Importantly, frequency of administration was critical to determine survival or death of mutant mice. 
In fact, daily administration maintained therapeutic albumin levels in plasma, and guaranteed normal 
brain development and survival. In contrast, HSA administration every 48 h resulted in a critical increase 
in tissue UCB leading to important abnormalities in cerebellar development, and death. This increase 
Figure 5. Plasma albumin, Bf and brain UCB at P16. Increment of Bf and tissue UCB in the HSA 5.0/48 h 
group 48 h after the last albumin administration. Comparison between P15 and P16 in P0-P10 PT, HSA 
5.0 g/kg/48 h and HSA 5.0 g/kg/24 h-treated mutant mice. (A) Plasma albumin levels decrease in HSA 5.0 g/
kg/48 h treated mutant mice. Values represent mean ± SD (g/L). t-test, *p < 0.05. P0-P10 PT (n = 6), HSA 
5.0 g/kg/48 h (n = 14), HSA 5.0 g/kg/24 h (n = 7); (B) Bf plasma levels at P15 and P16. Values represent 
mean ± SD (μ g/dL). One-way ANOVA test, *p < 0.05, ***p < 0.001. P0-P10 PT (n = 6), HSA 5.0 g/kg/48 h 
(n = 7), HSA 5.0 g/kg/24 h (n = 7); (C) Brain UCB content. The stripped bars represent the amount of UCB 
at P15, while the full colored bars represent the increment of UCB levels from P15 to P16 (the whole bars, 
stripped plus full colored, represent UCB levels at P16). t-test, *p < 0.05, ***p < 0.001. P0-P10 PT (n = 6), 
HSA 5.0 g/kg/48 h (n = 8), HSA 5.0 g/kg/24 h (n = 6). The number of animals analyzed at P15 is indicated 
in the legend to Figs 2 and 3 HSA, human serum albumin; PT, phototherapy; P, post-natal day; Bf, free 
bilirubin; ns, not significative.
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in plasma and tissue UCB levels was associated with an important decrease in plasma albumin lev-
els 48 h after the last administration (HSA 5.0 g/kg/48 h at P16). It remains unclear the reasons of the 
rapid decrease in plasma albumin concentration 48 h after administration since the reported life-time 
of monomeric albumin in humans is in the range of 28–36 days38. However, our finding is in line with 
that observed in analbuminemic patients and adult Gunn rats infused with HSA33,39,40, where plasma 
albumin levels increased immediately after infusion, but substantially decreased 24 h post-treatment. 
Moreover, it was shown that albumin half-life in mice infused with mouse albumin was 35 h41 while 
that of mice infused with HSA was 21 h42. We speculate that it could be related to its distribution in the 
Figure 6. Plasma markers of bilirubin neurotoxicity. The different parameters routinely used in the clinics 
to monitor hypebilirubinemia were analyzed at P16 as a function of tissue bilirubin in the cerebellum 
(nmol/g), to determine the best indicator of cerebellar bilirubin neurotoxicity. (A) Total bilirubin, TB (mg/
dL); (B) Bilirubin/albumin (B/A) ratio (μ mol/g); and (C) Unconjugated free (unbound) bilirubin, Bf (μ g/
dL). Each dot represents a single animal. P0-P10 PT (n = 6), HSA 5.0 g/kg/48 h (n = 8), and HSA 5.0 g/
kg/24 h (n = 6) HSA, human serum albumin; PT, phototherapy; P, post-natal day; UCB, unconjugated 
bilirubin; Bf, free bilirubin; ns, not significative.
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extravascular space of other body compartments, resulting in a reduction in the plasma levels, and/or to 
species-specific differences leading to faster albumin degradation42,43.
In line with our observations are Hosono et al.28 data, showing promising results in infants treated 
with a single infusion of albumin at the beginning of the PT treatment, resulting in a decrease of auditory 
brainstem response abnormalities. We cannot exclude that lower doses of albumin could have a similar 
or higher therapeutic effect if administered even more frequently (i.e., twice a day).
In the present work, the dosage scheme of 5.0 g/kg daily was the minimal one able to rescue mor-
tality. The usual dose administered in neonates is lower than the one used in this study (about 1.0 g/kg, 
administered i.v.)28,30, even though in some specific cases doses up to 4.5 g/kg were used without evident 
adverse effects31,32,44. Here, we did not observe any obvious secondary effects, even when animals were 
treated with the highest dose (7.5 g/kg every 24 h). Although effective, dose comparison between mice 
and neonates is not trivial, especially when different administrations routes are applied. In fact, due to 
the small size of the mouse neonates (about 2 g at P2), we adopted intraperitoneal injection, a procedure 
that results in a slower availability of administered HSA in the intravascular compartment, compared to 
intravenous administration, being routinely used in newborns. Therefore, we can speculate that the more 
frequent HSA administration and the use of the i.v. route in neonates may require the administration 
of lower doses than the ones used here. Thus, these procedures, in combination with the application of 
intensive phototherapy, may limit the concerns raised by the high HSA doses administered to the present 
model. However, the potential benefits of HSA application have to be more deeply investigated in human 
jaundiced babies, especially in preterm infants with very low weight at birth, being the most susceptible 
to bilirubin neurotoxicity.
Due to the elicited increase in plasma bilirubin, albumin administration to reduce bilirubin-induced 
neurological damage invalidates the use of plasma TB as an indicator of the overall risk of bilirubin 
neurotoxicity. Clinical indications in patients suggest that TB levels over a threshold value of ~20 mg/
dL, are poor discriminators of the individual risk of developing brain damage45,46. Hence, other more 
specific indicators are a clinical need.
Figure 7. Model of bilirubin mobilization by HSA administration. In normal conditions, the bilirubin-
binding capacity provided by albumin exceeds the amount of UCB (left). In severe hyperbilirubinemic 
conditions, UCB outnumbers the albumin-binding capacity, and the excess of UCB (free bilirubin) 
solubilizes in lipid-rich tissues, such as the brain and cerebellum (center), resulting in neurological 
damage. When plasma bilirubin-binding capacity is artificially increased by HSA administration, bilirubin 
is mobilized from tissues to the plasma compartment, resulting in safe levels of tissue UCB (right) and 
increased plasma UCB levels. Thus, bilirubin mobilization prevents neurological damage and rescues 
lethality in HSA-treated mutant mice UCB, unconjugated bilirubin; HSA, human serum albumin.
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It has been proposed that the ratio of bilirubin to albumin or B/A47 could be a valid parameter to 
approximate the risk of bilirubin neurotoxicity in neonates. B/A was endorsed by the American Academy 
of Pediatrics2 and routinely used to determine the threshold for ET14,47. Our data indicate that B/A 
ratio is a poor indicator of neurological damage and death in our mouse model. In fact, the B/A ratio, 
similarly to the TB values, was not able to accurately predict the outcome of the different groups of 
mice used here. However, this study differs markedly from the application of the B/A ratio to predict 
neurotoxicity risk in human neonates, in which bilirubin levels are elevated in the context of significant 
hypoalbuminemia. In fact, we artificially increased the plasma albumin concentration in the pups by 
repeated albumin administration. In recent results obtained in the BARTrial, the B/A ratio was found 
to be similarly effective as TSB in the management of hyperbilirubinemia in preterm infants to prevent 
neurodevelopmental damage48.
The concentrations in plasma of unbound unconjugated bilirubin, Bf, correlated strongly with the 
beneficial treatment effects. Accordingly, we provided here compelling supportive evidence that the accu-
rate determination of the free pool of bilirubin (Bf) concentration in plasma could act as an indicator of 
the risk of neurological damage.
The potential use of Bf in human patients, as a precise parameter to predict bilirubin-induced neu-
rological damage and kernicterus is supported by various studies25,46,49–51. These authors showed that 
defects in auditory brainstem response in a newborn population, caused by bilirubin-induced neurotox-
icity, correlates with Bf rather than total plasma bilirubin. In another study performed in extremely low 
birth weight infants, Bf was associated with death or adverse neurodevelopmental outcomes and was a 
better predictor than TB, since its correlation was independent of clinical status52. Consistently, a recent 
study shows that high Bf predicts kernicterus in extremely low birth weight Japanese infants51.
Based on our data in mice, albumin administration can clearly confer protection to bilirubin neuro-
toxicity and save lives. HSA beneficial effects were even obtained with the exclusive use of albumin, i.e as 
mono-therapy. It is reasonable to assume that similar added value is possible upon co-treatment with PT. 
Thus, this procedure could be used in therapy resistant hyperbilirubinemia or (imminent) kernicterus. It 
may also be helpful to acute patients when the concomitant implementation of ET is not easily or rapidly 
possible, either by patient related factors or infrastructure. We have previously shown in a preclinical rat 
model that PT treatment enhances the effect of albumin administration33,34. Indeed, we propose that the 
therapeutic synergy of intensive PT and frequent albumin administration, in combination with the con-
stant monitoring of free unbound bilirubin (Bf), may result in the most effective and feasible procedure 
to be applied to such jaundiced neonates.
ET is normally applied in the context of the clinical scenarios of infants presenting with hazardous 
hyperbilirubinemia or who fail to respond to PT2,14, with high risk of mortality and adverse events17–20. 
It is important to highlight that the procedure described here, which could be an efficient adjuvant treat-
ment to intensive phototherapy, is at the reach of most neonatal care units in a quick and secure manner, 
and should present almost no concerns regarding its safety profile.
In conclusion, the results presented here supports the potential use of albumin infusions in severe 
acute neonatal hyperbilirubinemia and in Crigler-Najjar patients, to limit/avoid bilirubin neurotoxicity 
in situations in which ET may be required. We also demonstrated that the dosage and administration 
frequency are critical parameters for its efficacy. Finally, our data provide evidence that in this lethal 
mouse model, plasma Bf concentration is the best marker to predict the risk of bilirubin-induced brain 
damage. Randomized clinical trials comparing the efficacy of albumin therapy versus other modalities 
are warranted to confirm our experimental data.
Methods
Animals. Mice were housed and handled according to institutional guidelines, and experimental pro-
cedures approved by the ICGEB board, with full respect to the EU Directive 2010/63/EU for animal 
experimentation. Ugt1 mutant mice in the FVB/NJ background have been generated previously36,37. 
Homozygous mutant animals were obtained from heterozygous matings. WT littermates were used as 
control. Average litters were of 9–10 pups. No loss of pups was observed. Animals used in this study 
were at least 99.8% FVB/NJ genetic background, obtained after more than ten backcrosses with wild type 
FVB/NJ mice. Mice were kept in a temperature-controlled environment with 12/12 h light/dark cycle. 
They received a standard chow diet and water ad libitum.
Phototherapy treatment. Phototherapy treatment was performed as previously described36. 
Animals of the P0-P10PT control group were exposed to blue fluorescent light (20 μ W/cm2/nm, Philips 
TL 20W/52 lamps; Philips, Amsterdam, The Netherlands) for 12 hours/day since birth up to postnatal 
day 10, and then maintained under normal light conditions.
Albumin treatment. Newborn mice were intraperitoneally (i.p.) injected with HSA (Albuman® ; 
solution for infusion, 200 g/L, fatty acid free) purchased from Sanquin (Amsterdam, The Netherlands). 
WT (injected control group) and mutant mice were injected from postnatal day 2 (P2) up to postna-
tal day 20 (P20), with 2.5 g/kg/48 h (n = 15), 5.0 g/kg/48 h (n = 15), 2.5 g/kg/24 h (n = 11), 5 g/kg/24 h 
(n = 15) and 7.5 g/kg/24 h (n = 12) and survival was monitored. Animals treated every 48h received HSA 
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administration at P2, P4, P6, P8, P10, P12, P14, P16, P18 and P20, while the 24 h group every 24 h, 
starting at P2 till P20.
Biochemical analyses of plasma samples. Blood samples were collected at different time points 
in mutant and WT littermates by cardiac puncture in EDTA-collecting tubes, at the moment of sacri-
ficing the animals, as previously described36. Total bilirubin (TB), Bf, and albumin were determined as 
described33,53,54.
Tissue bilirubin analysis. Tissues for bilirubin content determination were collected and analyzed 
as previously described53,55.
Rotarod analysis. At 1 month of age, the coordination and balance ability of mutant and WT mice 
were tested on a rotating cylinder with an accelerating apparatus, as previously described37.
Brain histology. Histological and immunofluorescence analysis of forebrain and cerebellum samples 
was performed as previously described36,37. The study was performed in a double-blind fashion: the 
genotype of the animals and the treatment were unknown to the surgeon, while a different investigator 
analyzed the data. Measurements were averaged for each animal.
Statistics. The Prism package (GraphPad Software, La Jolla, CA) was used to analyze the data. Results 
are expressed as mean ± s.d. Values of p < 0.05 were considered statistically significant. Depending on the 
experimental design, Student’s t-test or one-way ANOVA, with Bonferroni’s post-hoc comparison tests 
were used, as indicated in the legends to the figures and text. Correlation analyses were done using the 
Pearson coefficient to assess the linearity between two variables and calculate two-tailed p value (95% 
of confidence interval).
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